Heron Therapeutics
HRTX
182 hedge funds and large institutions have $1.34B invested in Heron Therapeutics in 2020 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 61 increasing their positions, 64 reducing their positions, and 29 closing their positions.
2.22% more ownership
Funds ownership: 97.77% → 99.99% (+2.2%)
1% more capital invested
Capital invested by funds: $1.33B → $1.34B (+$9.06M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 64
6% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $1.08M
4% less funds holding
Funds holding: 190 → 182 (-8)
28% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 29
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$31.3M |
| 2 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$17.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.89M |
| 4 |
O
OrbiMed
New York
|
+$8.29M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.62M |
Top Sellers
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$14.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.4M |
| 3 |
BlackRock
New York
|
-$7.66M |
| 4 |
Holocene Advisors
New York
|
-$5.9M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.61M |
HRTX Hedge Fund Activity: Q3 2020 in Review
182 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2020, worth a combined $1.34B — up 0.68% from $1.33B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of HRTX and 21 opened new positions — a net loss of 8 holders — while 64 trimmed existing stakes and 61 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $31.3M. The largest seller was Fidelity International, cutting an estimated $14.8M.
- 182 institutional investors held Heron Therapeutics (HRTX) as of Q3 2020, down from 190 in Q2 2020.
- Funds reported $1.34B of Heron Therapeutics stock for Q3 2020, up 0.68% quarter-over-quarter.
- 21 funds opened new Heron Therapeutics positions in Q3 2020 and 29 closed out, a net change of -8 holders.
- The largest Heron Therapeutics buyer in Q3 2020 was Consonance Capital Management, an estimated $31.3M added.
- The largest Heron Therapeutics seller in Q3 2020 was Fidelity International, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2020.